A candidate antibody therapeutic for atopic dermatitis has met its primary endpoint in a Phase 2a study using a novel treatment strategy. The therapy, KY1005, targets the OX40-ligand, a key regulator of the immune system. In the study, the compound showed a clinically meaningful improvement in disease activity compared with placebo, according to the developer Kymab Ltd.
